The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drug penetration in solid tumours
Minchinton, A. I., & Tannock, I. F. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1893 · Cited by 2,805
REDFERN, W., CARLSSON, L., DAVIS, A., LYNCH, W., MACKENZIE, I., PALETHORPE, S., SIEGL, P., STRANG, I., SULLIVAN, A., & WALLIS, R. (2003) · Cardiovascular Research · doi:10.1016/s0008-6363(02)00846-5 · Cited by 1,532
Changes in plasma protein binding have little clinical relevance
Benet, L. Z., & Hoener, B. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.121829 · Cited by 825
Parkinson’s Disease and Movement Disorders
(2005) · Jaypee Brothers Medical Publishers (P) Ltd. eBooks · doi:10.5005/jp/books/10587 · Cited by 798
Pang, K. S., & Rowland, M. (1977) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01059688 · Cited by 797
Drug-Like Properties: Concepts, Structure Design and Methods from ADME to Toxicity Optimization
Kerns, E. H., & Di, L. (2016) · Cited by 784
Self-citationRole of Pharmacokinetics and Metabolism in Drug Discovery and Development
Lin, J. H., & Lu, A. Y. H. (1997) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01340-1 · Cited by 708
Pharmacokinetic/pharmacodynamic data analysis : concepts and applications
Gabrielsson, J., & Weiner, D. (2002) · Cited by 704
Physicochemical Profiling (Solubility, Permeability and Charge State)
Avdeef, A. (2001) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026013395100 · Cited by 587
On The Rate and Extent of Drug Delivery to the Brain
Hammarlund-Udenaes, M., Fridén, M., Syvänen, S., & Gupta, A. (2008) · Pharmaceutical Research · doi:10.1007/s11095-007-9502-2 · Cited by 513
Pharmacokinetics and Tissue Penetration of Fluconazole in Humans
Brammer, K. W., Farrow, P. R., & Faulkner, J. K. (1990) · Clinical Infectious Diseases · doi:10.1093/clinids/12.supplement_3.s318 · Cited by 429
The importance of plasma protein binding in drug discovery
Trainor, G. L. (2007) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2.1.51 · Cited by 348
Significance of Protein Binding in Pharmacokinetics and Pharmacodynamics
Schmidt, S., Gonzalez, D., & Derendorf, H. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21916 · Cited by 335
Lau, Y. Y., Huang, Y., Frassetto, L., & Benet, L. Z. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100038 · Cited by 327
Rolan, P. (1994) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1994.tb04251.x · Cited by 301
Kang, J., Wang, L., Chen, X.-L., Triggle, D. J., & Rampe, D. (2001) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12364-4 · Cited by 282
Leach, A. G., Jones, H. D., Cosgrove, D. A., Kenny, P. W., Ruston, L., MacFaul, P., Wood, J. M., Colclough, N., & Law, B. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0605233 · Cited by 277
Parkinson's Disease and Movement Disorders
Jankovic, J. J., & Tolosa, E. (2003) · European Journal of Neurology · doi:10.1046/j.1468-1331.2003.00637.x · Cited by 264
DEVELOPMENT OF A COMPUTATIONAL APPROACH TO PREDICT BLOOD-BRAIN BARRIER PERMEABILITY
Liu, X., Tu, M., Kelly, R. S., Chen, C., & Smith, B. J. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.32.1.132 · Cited by 244
Maurer, T. S., DeBartolo, D. B., Tess, D. A., & Scott, D. O. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.001222 · Cited by 214
CSF as a Surrogate for Assessing CNS Exposure: An Industrial Perspective
Lin, J. (2008) · Current Drug Metabolism · doi:10.2174/138920008783331077 · Cited by 187
Summerfield, S. G., Stevens, A. J., Cutler, L., del Carmen Osuna, M., Hammond, B., Tang, S.-P., Hersey, A., Spalding, D. J., & Jeffrey, P. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.092916 · Cited by 175
Compound lipophilicity for substrate binding to human P450s in drug metabolism
Lewis, D. F. V., Jacobs, M. N., & Dickins, M. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03115-0 · Cited by 172
Molla, A., Vasavanonda, S., Kumar, G., Sham, H. L., Johnson, M., Grabowski, B., Denissen, J. F., Kohlbrenner, W., Plattner, J. J., Leonard, J. M., et al. (1998) · Virology · doi:10.1006/viro.1998.9383 · Cited by 171
Testa, B., Krämer, S. D., Wunderli‐Allenspach, H., & Folkers, G. (2006) · Cited by 166
Liu, X., Smith, B. J., Chen, C., Callegari, E., Becker, S. L., Chen, X., Cianfrogna, J., Doran, A. C., Doran, S. D., Gibbs, J. P., et al. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.008201 · Cited by 163
Wood, A., & Armour, D. (2005) · Progress in Medicinal Chemistry · doi:10.1016/s0079-6468(05)43007-6 · Cited by 161
Kalvass, J. C., Olson, E. R., Cassidy, M. P., Selley, D. E., & Pollack, G. M. (2007) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.119560 · Cited by 161
Clinical Pharmacokinetics of Cimetidine
Somogyi, A. A., & Gugler, R. (1983) · Clinical Pharmacokinetics · doi:10.2165/00003088-198308060-00001 · Cited by 156
Clinical Pharmacokinetics of Fluconazole in Superficial and Systemic Mycoses
Debruyne, D. (1997) · Clinical Pharmacokinetics · doi:10.2165/00003088-199733010-00005 · Cited by 153
Sustained Activation of a G Protein-coupled Receptor via “Anchored” Agonist Binding
Green, S. A., Spasoff, A. P., Coleman, R. A., Johnson, M. W., & Liggett, S. B. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.39.24029 · Cited by 151
Wan, H., Rehngren, M., Giordanetto, F., Bergström, F., & Tunek, A. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070375w · Cited by 143
Free drug fraction vs. free drug concentration: a matter of frequent confusion
Toutain, P., & Bousquet‐mélou, A. (2002) · Journal of Veterinary Pharmacology and Therapeutics · doi:10.1046/j.1365-2885.2002.00442.x · Cited by 133
Clopidogrel: a review of its mechanism of action
Savi, P., Nurden, P., Nurden, A. T., Levy-Toledano, S., & Herbert, J. M. (1998) · Platelets · doi:10.1080/09537109876799 · Cited by 133
Strategies to assess blood–brain barrier penetration
Di, L., Kerns, E. H., & Carter, G. T. (2008) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.3.6.677 · Cited by 122
Self-citationPharmacokinetics and Metabolism in Drug Design
Smith, D. A., Waterbeemd, H. V. D. 1., & Walker, D. K. (2003) · European Journal of Medicinal Chemistry · doi:10.1016/s0223-5234(03)00124-7 · Cited by 112
Self-citationHattori, K., Kido, Y., Yamamoto, H., Ishida, J., Kamijo, K., Murano, K., Ohkubo, M., Kinoshita, T., Iwashita, A., Mihara, K., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm0499256 · Cited by 99
Suzuki, H., Terasaki, T., & Sugiyama, Y. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(97)00503-6 · Cited by 93
Ligands, their receptors and … plasma membranes
Vauquelin, G., & Packeu, A. (2009) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2009.07.022 · Cited by 87
Protein Binding Drug Displacement Interactions
MacKichan, J. J. (1989) · Clinical Pharmacokinetics · doi:10.2165/00003088-198916020-00001 · Cited by 87
Design of a potent, soluble glucokinase activator with excellent in vivo efficacy
McKerrecher, D., Allen, J. V., Caulkett, P. W. R., Donald, C. S., Fenwick, M. L., Grange, E., Johnson, K. M., Johnstone, C., Jones, C. D., Pike, K. G., et al. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.02.022 · Cited by 85
Cholesterol alters the binding of Ca2+ channel blockers to the membrane lipid bilayer.
Mason, R. P., Moisey, D. M., & Shajenko, L. (1992) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)08879-0 · Cited by 84
Strategies to optimize brain penetration in drug discovery.
Liu, X., & Chen, C. (2005) · PubMed · Cited by 80
P-glycoprotein related drug interactions: clinical importance and a consideration of disease states
Lee, C. A., Cook, J., Reyner, E. L., & Smith, D. A. (2010) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425251003610640 · Cited by 80
Self-citationChallenges for blood–brain barrier (BBB) screening
Jeffrey, P., & Summerfield, S. G. (2007) · Xenobiotica · doi:10.1080/00498250701570285 · Cited by 79
Gabrielsson, J., & Green, A. R. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.157172 · Cited by 70
Fluconazole and Other Azoles: Translation of in Vitro Activity to in Vivo and Clinical Efficacy
Troke, P. F., Andrews, R. J., Pye, G. W., & Richardson, K. (1990) · Clinical Infectious Diseases · doi:10.1093/clinids/12.supplement_3.s276 · Cited by 64
Pharmacokinetics and Metabolism in Drug Design
Smith, D. A., Waterbeemd, H. V. D., & Walker, D. K. (2006) · Methods and principles in medicinal chemistry · doi:10.1002/3527608222 · Cited by 62
Self-citationClinical Significance of Drug Binding, Protein Binding, and Binding Displacement Drug Interactions
DeVane, C. L., & PharmD (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4210 · Cited by 44
The (ir)relevance of plasma protein binding of anticancer drugs
Sparreboom, A. (2001) · The Netherlands Journal of Medicine · doi:10.1016/s0300-2977(01)00157-7 · Cited by 41
Webster, R., Allan, G. A., Anto-Awuakye, K., Harrison, A., Kidd, T., Leishman, D. J., Phipps, J., & Walker, D. K. (2001) · Xenobiotica · doi:10.1080/00498250110054632 · Cited by 40
KA-672 inhibits rat brain acetylcholinesterase in vitro but not in vivo
Hilgert, M., Nöldner, M., Chatterjee, S. S., et al. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(99)00149-4 · Cited by 35
Naproxen concentrations in plasma and synovial fluid and effects on prostanoid concentrations.
Day, R. O., Francis, H., Vial, J. H., Geißlinger, G., & Williams, K. M. (1995) · PubMed · Cited by 32
Impact of plasma-protein binding on receptor occupancy: An analytical description
Peletier, L. A., Benson, N., & van der Graaf, P. H. (2008) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2008.09.014 · Cited by 28
Moss, N., Choi, Y., Cogan, D. A., et al. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.02.126 · Cited by 26
Kwan, Y. W., Bangalore, R., Lakitsch, M., Glossmann, H. H., & Kass, R. S. (1995) · Journal of Molecular and Cellular Cardiology · doi:10.1016/s0022-2828(08)80024-7 · Cited by 22
Kerns, E. H., & Di, L. (2008) · Elsevier eBooks · doi:10.1016/b978-012369520-8.50008-5 · Cited by 22
Self-citationHussein, Z., Evans, A. M., & Rowland, M. (1993) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600820904 · Cited by 21
Zhu, P., Zheng, W., Auld, D. S., Jadhav, A., MacArthur, R., Olson, K. R., Peng, K., Dotimas, H., Austin, C. P., & Inglese, J. (2008) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/138620708785204045 · Cited by 16
Corticotropin-releasing factor receptor antagonists
Gilligan, P. J. (2006) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.16.7.913 · Cited by 12
Cited by
Human serum albumin: From bench to bedside
Fanali, G., di Masi, A., Trezza, V., Marino, M., Fasano, M., & Ascenzi, P. (2012) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2011.12.002 · Cited by 1,931
Strategies to Address Low Drug Solubility in Discovery and Development
Williams, H. D., Trevaskis, N. L., Charman, S. A., Shanker, R. M., Charman, W. N., Pouton, C. W., & Porter, C. J. H. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.005660 · Cited by 1,570
The determination and interpretation of the therapeutic index in drug development
Muller, P. Y., & Milton, M. N. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3801 · Cited by 563
Human serum albumin, systemic inflammation, and cirrhosis
Arroyo, V., García-Martinez, R., & Salvatella, X. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.04.012 · Cited by 560
CNS Drug Design: Balancing Physicochemical Properties for Optimal Brain Exposure
Rankovic, Z. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501535r · Cited by 548
Metadata
- Authors
- Smith, D. A., Di, L., & Kerns, E. H.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2010-12
- Volume
- 9
- Issue
- 12
- Pages
- 929-939
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1974290383
- Cited by
- 898
- References
- 60
- FWCI
- 1.92
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.